Himalaya Nutravedics IPO is a BSE SME Book Built public issue of Himalaya Nutravedics India Limited. The IPO comprises an entirely fresh issue of 24,99,600 equity shares with a face value of ₹10 per share. At the upper price band of ₹106, the issue size aggregates to approximately ₹26.50 crore. There is no Offer for Sale component in the issue.
Himalaya Nutravedics IPO opens for subscription on 22 September 2026 and closes on 24 September 2026. The basis of allotment is expected to be finalised on 25 September 2026, followed by refund initiation and credit of shares to demat accounts on 28 September 2026. The equity shares are proposed to be listed on the BSE SME platform on 29 September 2026.
The IPO price band has been fixed at ₹100 to ₹106 per equity share. The minimum application lot is 1,200 shares, while retail investors are required to apply for a minimum of 2 lots, or 2,400 shares. At the upper price band, the minimum retail investment is ₹2,54,400. The minimum application for S-HNI investors is 3 lots, or 3,600 shares, amounting to ₹3,81,600 at the upper price band.
Nirbhay Capital Services Private Limited is the Book Running Lead Manager of the issue and KFin Technologies Limited is the registrar. The company operates in the Ayurvedic and nutraceutical products segment and is engaged in manufacturing, marketing and distribution of Ayurvedic and nutraceutical formulations in India, along with third-party contract manufacturing services.
Himalaya Nutravedics India Limited has reported strong growth in its financial performance. Total income increased from ₹14.43 crore in FY2024 to ₹21.00 crore in FY2025 and further to ₹43.12 crore in FY2026. Profit after tax increased from ₹0.43 crore in FY2024 to ₹2.23 crore in FY2025 and ₹7.39 crore in FY2026.
Table of Contents
Himalaya Nutravedics IPO Details Information
| Particular | Details |
|---|---|
| IPO Name | Himalaya Nutravedics IPO |
| Company Name | Himalaya Nutravedics India Limited |
| IPO Type | Book Built Issue |
| IPO Category | SME IPO |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹100 to ₹106 Per Share |
| Issue Size | ₹26.50 Crore |
| Fresh Issue | 24,99,600 Equity Shares |
| Offer for Sale | Nil |
| IPO Open Date | 22 September 2026 |
| IPO Close Date | 24 September 2026 |
| Anchor Investor Bidding | To Be Announced |
| Basis of Allotment | 25 September 2026 |
| Refund Initiation | 28 September 2026 |
| Shares Credited to Demat Account | 28 September 2026 |
| Listing Date | 29 September 2026 |
| Listing Exchange | BSE SME |
| Lot Size | 1,200 Shares |
| Registrar | KFin Technologies Limited |
| Book Running Lead Managers | Nirbhay Capital Services Private Limited |
Himalaya Nutravedics IPO is a fresh capital issue of 24,99,600 equity shares. Based on the upper price band of ₹106 per share, the issue aggregates to approximately ₹26.50 crore. The company’s post-issue shareholding is expected to increase to 88,06,320 equity shares from 63,06,720 shares before the issue.
The IPO is structured as a Book Built SME issue and will be listed on the BSE SME platform. The proceeds from the fresh issue will be used primarily for funding working capital requirements, business development and digital marketing activities, and general corporate purposes.
Himalaya Nutravedics IPO Dates
| IPO Event | Date |
|---|---|
| Anchor Investor Bidding | To Be Announced |
| IPO Opening Date | 22 September 2026 |
| IPO Closing Date | 24 September 2026 |
| Basis of Allotment | 25 September 2026 |
| Refund Initiation | 28 September 2026 |
| Shares Credited to Demat Account | 28 September 2026 |
| Listing Date | 29 September 2026 |
Himalaya Nutravedics IPO will remain open for subscription from 22 September 2026 to 24 September 2026. The allotment is scheduled for 25 September 2026, while refunds and demat credit are expected on 28 September 2026. The proposed listing date on BSE SME is 29 September 2026.
Investors should note that the timetable is subject to the completion of the applicable IPO processes. Any changes to the timetable will be communicated through the relevant exchange and company announcements.
Himalaya Nutravedics IPO Reservation
| Investor Category | Reservation |
|---|---|
| QIB | Not more than 50% of the Net Offer |
| NII | Not less than 15% of the Net Offer |
| RII | Not less than 35% of the Net Offer |
The IPO reservation follows the applicable SME public issue framework. Not more than 50% of the net offer is reserved for Qualified Institutional Buyers, while not less than 15% is reserved for Non-Institutional Investors and not less than 35% for Retail Individual Investors.
The final allocation within each category will depend on the valid applications received during the subscription period.
Himalaya Nutravedics IPO Lot Size
Investors can bid for a minimum of 2,400 shares and in multiples of 1,200 shares thereafter.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual Investors (IND) Minimum | 2 | 2,400 | ₹2,54,400 |
| Individual Investors (IND) Maximum | 2 | 2,400 | ₹2,54,400 |
| S-HNI Minimum | 3 | 3,600 | ₹3,81,600 |
| S-HNI Maximum | 7 | 8,400 | ₹8,90,400 |
| B-HNI Minimum | 8 | 9,600 | ₹10,17,600 |
The application amounts shown above are calculated using the upper price band of ₹106 per share. Retail investors need to apply for a minimum of two lots, representing 2,400 shares and an investment of ₹2,54,400.
S-HNI investors can apply for a minimum of three lots, while the B-HNI category begins at eight lots. The final amount payable will depend on the number of shares applied for and the applicable issue price.
About Himalaya Nutravedics India Limited
Himalaya Nutravedics India Limited is a Hyderabad-based company engaged in the manufacture, marketing and distribution of Ayurvedic and nutraceutical formulations in India. The company also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical businesses.
The company was incorporated in June 2022 and operates from its manufacturing facility at Cherlapally, Hyderabad, Telangana. Its business combines branded products with contract manufacturing activities, giving it exposure to both its own product portfolio and manufacturing requirements of other businesses.
The company’s product portfolio includes classical Ayurvedic formulations, proprietary Ayurvedic formulations and nutraceutical products. Its products are available in multiple dosage forms, including soft gelatin capsules, hard gelatin capsules, tablets, liquid orals, medicated oils and protein powders.
The company serves different therapeutic and wellness categories, including digestive health, immunity, metabolic health, pain management, diabetes management, women’s health and general wellness.
The company has expanded its presence across multiple Indian markets and has developed a distribution network covering various states. Its products are marketed through healthcare practitioners and other distribution channels.
The company’s manufacturing operations and product portfolio position it within the broader Ayurvedic, herbal and nutraceutical products industry. The business is also subject to applicable regulatory requirements relating to Ayurvedic products, nutraceuticals, food products and manufacturing.
Business Operations
Himalaya Nutravedics India Limited operates through a combination of own-brand manufacturing and third-party contract manufacturing.
The own-brand business includes classical Ayurvedic formulations based on established Ayurvedic texts, proprietary Ayurvedic formulations developed within Ayurvedic principles and nutraceutical products intended for preventive health and wellness.
The company manufactures products in several dosage forms. These include soft gelatin capsules, hard gelatin capsules, tablets, liquid oral formulations, medicated oils and protein powders. This diversified product format allows the company to serve different product categories and consumer requirements.
The company also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies. Contract manufacturing provides an additional revenue channel and enables the company to utilise its manufacturing capabilities for products marketed by other businesses.
Its product portfolio covers multiple therapeutic and wellness areas. These include gut health, cardiac and metabolic wellness, diabetes management, pain management, immunity, women’s health and general wellness.
The company’s manufacturing facility is located in Cherlapally, Hyderabad. The company has developed its operations around manufacturing, marketing and distribution, supported by a network covering multiple Indian states.
The combination of branded products and contract manufacturing provides the company with a diversified operating model. However, the business also requires continuous attention to product quality, regulatory compliance, manufacturing capacity, distribution and marketing.
Industry Overview
The Ayurvedic and nutraceutical products industry forms part of India’s broader pharmaceutical, healthcare, wellness and preventive-health ecosystem. Demand for traditional healthcare products and nutritional supplements has increased alongside consumer interest in preventive healthcare, wellness and lifestyle-related health management.
Ayurvedic products have an established presence in the Indian healthcare market, while nutraceutical products have gained attention due to increasing awareness of nutrition, immunity, fitness and preventive healthcare.
The industry includes manufacturers of classical Ayurvedic formulations, proprietary products, herbal products, nutritional supplements and other wellness-focused products. Companies operating in this sector compete through product quality, formulations, distribution reach, brand recognition, pricing and product innovation.
The growth of organised retail, e-commerce and healthcare distribution channels can provide additional opportunities for Ayurvedic and nutraceutical manufacturers to reach consumers in different parts of the country.
At the same time, manufacturers need to comply with applicable regulatory requirements and maintain consistent quality standards. Product development, manufacturing capacity, raw material availability, marketing expenses and competition can also influence business performance.
Business Strategy
Himalaya Nutravedics India Limited’s business strategy focuses on expanding its manufacturing capabilities, strengthening its product portfolio and increasing its market reach in Ayurvedic and nutraceutical products.
The company combines own-brand products with third-party contract manufacturing. This allows it to participate in the branded Ayurvedic and nutraceutical market while also serving other companies that require manufacturing capabilities.
Business development and digital marketing are among the stated objects of the IPO. The company intends to use part of the issue proceeds for these activities, which can support customer acquisition, brand visibility and expansion of its market presence.
The company can also leverage its existing manufacturing infrastructure to introduce or expand products across different therapeutic and wellness categories.
Its presence across multiple states provides a foundation for further distribution expansion. Increasing demand for preventive healthcare and wellness products may provide additional opportunities for the company.
However, sustainable growth will depend on effective utilisation of working capital, maintaining product quality, managing manufacturing operations, expanding distribution and controlling marketing and operating costs.
Himalaya Nutravedics IPO Financial Information
Himalaya Nutravedics India Limited has reported significant improvement in revenue and profitability over the last three financial years.
Total income increased from ₹14.43 crore in FY2024 to ₹20.997 crore in FY2025 and ₹43.12 crore in FY2026. This represents strong year-on-year growth in the latest reported financial period.
Profit after tax increased from ₹0.43 crore in FY2024 to ₹2.23 crore in FY2025 and ₹7.39 crore in FY2026. EBITDA also increased from ₹0.94 crore in FY2024 to ₹2.99 crore in FY2025 and ₹8.10 crore in FY2026.
Net worth increased substantially during the period, reaching ₹16.38 crore in FY2026 compared with ₹6.75 crore in FY2025. Borrowings stood at ₹5.13 crore in FY2026.
The financial figures indicate strong recent growth in revenue, EBITDA and profitability. Investors should evaluate this growth together with the company’s valuation, working capital requirements, industry competition and future expansion plans.
Himalaya Nutravedics Financial Summary
| Particulars | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Assets | ₹6.09 Cr | ₹10.82 Cr | ₹24.42 Cr |
| Total Income | ₹14.43 Cr | ₹21.00 Cr | ₹43.12 Cr |
| Profit After Tax | ₹0.43 Cr | ₹2.23 Cr | ₹7.39 Cr |
| EBITDA | ₹0.94 Cr | ₹2.99 Cr | ₹8.10 Cr |
| Net Worth | ₹1.34 Cr | ₹6.75 Cr | ₹16.38 Cr |
| Reserves and Surplus | ₹0.53 Cr | ₹2.76 Cr | ₹10.07 Cr |
| Total Borrowing | ₹3.24 Cr | ₹1.76 Cr | ₹5.13 Cr |
The company recorded strong growth in total income during FY2026. Total income more than doubled from ₹21.00 crore in FY2025 to ₹43.12 crore in FY2026.
PAT increased from ₹2.23 crore to ₹7.39 crore over the same period, while EBITDA increased from ₹2.99 crore to ₹8.10 crore.
Net worth also expanded from ₹6.75 crore in FY2025 to ₹16.38 crore in FY2026. Borrowings increased from ₹1.76 crore to ₹5.13 crore during the same period.
The improvement in profitability and net worth is an important part of the company’s recent financial performance. Investors should also consider whether the growth rate can be maintained after listing and how effectively the company deploys the IPO proceeds.
Himalaya Nutravedics IPO Key Performance Indicators (KPIs)
| KPI | Mar 31, 2026 |
|---|---|
| ROE | 63.87% |
| ROCE | 36.41% |
| Debt/Equity | 0.31 |
| RoNW | 45.12% |
| PAT Margin | 17.16% |
| EBITDA Margin | 18.82% |
| NAV | ₹26.70 |
| Price to Book Value | 3.97 |
The company’s FY2026 financial ratios indicate strong profitability and returns on capital. ROE stood at 63.87%, while ROCE was 36.41%. The Debt-to-Equity ratio was 0.31.
The company reported an RoNW of 45.12%, a PAT margin of 17.16% and an EBITDA margin of 18.82%. NAV stood at ₹26.70 per share.
At the upper IPO price of ₹106, the valuation should be considered alongside the company’s reported earnings, NAV, return ratios and post-issue capital structure.
The company’s strong recent earnings growth provides important context for evaluating the IPO, but historical financial performance does not by itself indicate future returns.
Objects of the Himalaya Nutravedics IPO
The company proposes to utilise the Net Proceeds from the Issue towards the following objects:
- Funding Working Capital Requirements.
- Business Development and Digital Marketing Activities.
- General Corporate Purposes.
| # | Issue Objects | Estimated Amount (₹ Cr.) |
|---|---|---|
| 1 | Funding Working Capital Requirements | 13.75 |
| 2 | Business Development and Digital Marketing Activities | 7.50 |
| 3 | General Corporate Purposes | Balance amount |
| Total identified allocation | 21.25 |
A significant portion of the IPO proceeds is proposed to be used for working capital requirements. This can support the company’s operating cycle and provide funding for its business requirements as operations expand.
The company also proposes to allocate ₹7.50 crore towards business development and digital marketing activities. These activities can support customer acquisition, market expansion and increased visibility for the company’s products.
The remaining amount after the specified uses and applicable issue-related expenses is proposed to be utilised for general corporate purposes.
Himalaya Nutravedics IPO Listing Performance
| Particular | Value |
|---|---|
| Listing Exchange | BSE SME |
| Listing Date | 29 September 2026 |
| Issue Price | To Be Determined Within ₹100–₹106 |
| Listing Price | To Be Updated |
| Listing Gain | To Be Updated |
| Listing Gain (%) | To Be Updated |
Himalaya Nutravedics IPO is scheduled to list on the BSE SME platform on 29 September 2026.
The final issue price will be determined within the IPO price band of ₹100 to ₹106 per equity share. The actual listing price and listing performance will be available only after trading begins on the exchange.
Listing performance represents the initial market price movement after the IPO, while the company’s long-term performance will depend on its financial results, business expansion, competitive position and execution.
Himalaya Nutravedics IPO Subscription Status
The Himalaya Nutravedics IPO subscription period begins on 22 September 2026 and closes on 24 September 2026. Category-wise subscription figures will be available during the bidding period.
Investors should review the QIB, NII and retail subscription figures separately because demand can differ significantly between investor categories.
The final subscription figures will be available after the IPO closes and will reflect the total number of valid bids received against the shares offered.
Himalaya Nutravedics IPO Subscription
| Investor Category | Subscription |
|---|---|
| QIB | To Be Updated |
| NII | To Be Updated |
| RII | To Be Updated |
| Employee Category | To Be Updated |
| Total Subscription | To Be Updated |
The subscription figures will be updated once bidding begins. The final subscription multiple will be calculated after the close of the IPO based on valid applications received from different investor categories.
Himalaya Nutravedics IPO Review
Himalaya Nutravedics India Limited operates in the Ayurvedic and nutraceutical products segment and has developed a business model combining own-brand products with third-party contract manufacturing.
The company’s product portfolio covers several dosage forms and therapeutic categories. This provides exposure to different segments of the Ayurvedic and nutraceutical market rather than relying on a single product category.
The company has also reported strong financial growth. Total income increased from ₹21.00 crore in FY2025 to ₹43.12 crore in FY2026, while PAT increased from ₹2.23 crore to ₹7.39 crore. EBITDA increased from ₹2.99 crore to ₹8.10 crore during the same period.
The company reported an EBITDA margin of 18.82% and PAT margin of 17.16% for FY2026. Its ROE was 63.87% and ROCE was 36.41%.
The IPO proceeds are primarily intended to support working capital and business development activities. The allocation towards digital marketing is relevant to the company’s branded-product strategy and expansion of market reach.
The company’s business is also exposed to the competitive Ayurvedic and nutraceutical market. Product quality, regulatory compliance, brand development, distribution, manufacturing capacity and customer demand will influence future performance.
The company is relatively young, having been incorporated in 2022, and its financial performance has grown rapidly from a smaller base. Investors should therefore evaluate the sustainability of recent growth along with the IPO valuation.
At the upper price band of ₹106, the issue represents a post-issue market capitalisation of approximately ₹93.35 crore. Investors should compare this valuation with the company’s FY2026 earnings, NAV, profitability ratios and growth prospects.
The IPO should be evaluated on the basis of the final issue price, business fundamentals, financial performance, industry conditions, proposed use of funds and associated risk factors.
Himalaya Nutravedics IPO Strengths
- Strong growth in total income during FY2024-FY2026.
- Significant improvement in profit after tax.
- Growth in EBITDA and operating profitability.
- Diversified portfolio of Ayurvedic and nutraceutical formulations.
- Presence across multiple dosage forms and therapeutic categories.
- Combination of own-brand products and third-party contract manufacturing.
- Exposure to the growing preventive healthcare and wellness market.
- Strong FY2026 ROE and ROCE.
- Relatively low Debt-to-Equity ratio of 0.31 in FY2026.
- IPO proceeds include funding for working capital and business development.
Himalaya Nutravedics IPO Risk Factors
- The company operates in a competitive Ayurvedic and nutraceutical products market.
- The company is relatively young and has a limited operating history compared with established industry participants.
- Its future growth depends on successfully expanding its product portfolio and distribution network.
- Regulatory requirements applicable to Ayurvedic and nutraceutical products may affect operations.
- Product quality issues or regulatory non-compliance could adversely affect the business.
- Changes in consumer preferences may affect demand for particular products.
- The company needs sufficient working capital to support its business operations and growth.
- Marketing and brand-building activities may require continued expenditure.
- Dependence on third-party contract manufacturing customers can create customer concentration risks.
- Raw material availability and prices may affect manufacturing costs.
- Competition from established Ayurvedic, pharmaceutical and nutraceutical companies may affect margins.
- The company’s recent financial growth has occurred from a relatively small revenue base.
- Any slowdown in revenue growth could affect profitability and valuation.
- Expansion into new markets may involve additional distribution and marketing costs.
- The company operates in an industry where regulatory and quality standards are important to continued operations.
Himalaya Nutravedics IPO Promoters
Himalaya Nutravedics India Limited is promoted by Rohit Asawa, Divya Asawa, Chanda Asawa and Rama Raju Penmatsa.
The promoters have been associated with the company’s development and business operations. Rohit Asawa is identified as the Managing Director of the company, while the promoter group holds a significant portion of the pre-issue share capital.
Himalaya Nutravedics IPO Promoters Details
| Promoter | Designation |
|---|---|
| Rohit Asawa | Promoter & Managing Director |
| Divya Asawa | Promoter & Director |
| Chanda Asawa | Promoter |
| Rama Raju Penmatsa | Promoter |
The company has 63,06,720 shares before the IPO and proposes to issue 24,99,600 fresh equity shares. After the issue, the paid-up equity share capital is expected to increase to 88,06,320 shares.
Himalaya Nutravedics IPO Management Team
| Name | Designation |
|---|---|
| Rohit Asawa | Managing Director |
| Divya Asawa | Director |
| Ramya Inala | Director |
| Abhisheak Dhoot | Director |
| Pooja Biyani | Company Secretary |
| Krishna Kanth Sarda | Chief Financial Officer |
The company is managed by a board and key managerial personnel responsible for business operations, corporate governance, financial management and compliance.
Rohit Asawa serves as Managing Director. Divya Asawa, Ramya Inala and Abhisheak Dhoot are identified as directors in available corporate records. Pooja Biyani and Krishna Kanth Sarda are identified as the Company Secretary and Chief Financial Officer respectively in the latest available corporate information.
Himalaya Nutravedics IPO Registrar Details
| Particular | Details |
|---|---|
| Registrar Name | KFin Technologies Limited |
| Website | KFin Technologies IPO Portal |
| IPO Allotment Status | To Be Updated After Allotment |
| Email ID | [email protected] |
| Contact Number | 040-79615565 |
KFin Technologies Limited is the registrar to the Himalaya Nutravedics IPO. The registrar is responsible for processing IPO applications, finalising the basis of allotment, processing refunds and facilitating the credit of allotted shares into investors’ demat accounts.
Investors will be able to check their Himalaya Nutravedics IPO allotment status through the registrar’s IPO allotment facility after the basis of allotment is finalised.
Himalaya Nutravedics IPO Lead Manager Details
| Particular | Details |
|---|---|
| Lead Managers | Nirbhay Capital Services Private Limited |
Nirbhay Capital Services Private Limited is the Book Running Lead Manager for the Himalaya Nutravedics IPO. The lead manager is responsible for managing and coordinating various aspects of the public issue process.
Himalaya Nutravedics India Limited Contact Details
| Particular | Details |
|---|---|
| Company Name | Himalaya Nutravedics India Limited |
| Registered Office | Plot No. 101/A, Phase-III, Industrial Development Park, Cherlapally, Uppal, Hyderabad, Telangana – 500051 |
| Website | www.himalayanutravedics.com |
| Email ID | [email protected] |
Himalaya Nutravedics India Limited operates from its facility at Cherlapally, Hyderabad, Telangana. The company’s official website provides information about its business, products and IPO-related documents.
How to Check Himalaya Nutravedics IPO Allotment Status
Investors can check the Himalaya Nutravedics IPO allotment status after the basis of allotment is finalised through the registrar’s website or the BSE IPO portal.
Through KFin Technologies Limited
- Visit the official KFin Technologies IPO allotment portal.
- Select Himalaya Nutravedics IPO from the available IPO list.
- Choose PAN Number, Application Number, or DP/Client ID.
- Enter the required details correctly.
- Submit the information to view the allotment status.
Through BSE
- Visit the official BSE IPO allotment page.
- Select Himalaya Nutravedics IPO from the available IPO list.
- Enter your PAN Number or Application Number.
- Complete the verification process if required.
- Click Search to view the allotment result.
Himalaya Nutravedics IPO Conclusion
Himalaya Nutravedics IPO is a BSE SME Book Built issue comprising a fresh issue of 24,99,600 equity shares. The IPO price band has been fixed at ₹100 to ₹106 per share and the issue is scheduled to open on 22 September 2026 and close on 24 September 2026.
The company operates in the Ayurvedic and nutraceutical products segment and manufactures, markets and distributes various formulations in India. Its business model includes both own-brand products and third-party contract manufacturing.
The company has reported strong financial growth over the last three years. Total income increased from ₹14.43 crore in FY2024 to ₹43.12 crore in FY2026, while PAT increased from ₹0.43 crore to ₹7.39 crore. EBITDA also increased substantially during the same period.
The IPO proceeds are proposed to be used primarily for working capital requirements and business development and digital marketing activities, along with general corporate purposes. These funds are intended to support the company’s operating requirements and expansion plans.
At the same time, investors should consider the risks associated with competition, regulatory requirements, product quality, working capital, customer concentration, raw material costs and the company’s relatively short operating history.
The final investment assessment should consider the IPO valuation, financial performance, business model, industry outlook, proposed use of proceeds and risk factors. Investors should also review the company’s final offer documents before making an investment decision.
Himalaya Nutravedics IPO FAQs
What is Himalaya Nutravedics IPO?
Himalaya Nutravedics IPO is a Book Built SME public issue of Himalaya Nutravedics India Limited. The issue comprises 24,99,600 fresh equity shares and is proposed to be listed on the BSE SME platform.
What is the price band of Himalaya Nutravedics IPO?
The Himalaya Nutravedics IPO price band is ₹100 to ₹106 per equity share.
What is the issue size of Himalaya Nutravedics IPO?
The Himalaya Nutravedics IPO is an issue of 24,99,600 fresh equity shares. At the upper price band of ₹106 per share, the issue size is approximately ₹26.50 crore.
When will Himalaya Nutravedics IPO open?
The Himalaya Nutravedics IPO will open for subscription on 22 September 2026.
When will Himalaya Nutravedics IPO close?
The Himalaya Nutravedics IPO will close for subscription on 24 September 2026.
What is the lot size of Himalaya Nutravedics IPO?
The Himalaya Nutravedics IPO lot size is 1,200 shares. Retail investors need to apply for a minimum of two lots, or 2,400 shares.
What is the minimum investment required for Himalaya Nutravedics IPO?
At the upper price band of ₹106 per share, the minimum retail application for two lots of 2,400 shares requires an investment of ₹2,54,400.
Who is the registrar of Himalaya Nutravedics IPO?
KFin Technologies Limited is the registrar to the Himalaya Nutravedics IPO.
Who is the lead manager of Himalaya Nutravedics IPO?
Nirbhay Capital Services Private Limited is the Book Running Lead Manager of the Himalaya Nutravedics IPO.
When will Himalaya Nutravedics IPO be listed?
Himalaya Nutravedics IPO is proposed to list on the BSE SME platform on 29 September 2026.
